Predictors of the progression of dementia with Lewy bodies
Objective: To define predictors of the progression of dementia with Lewy bodies (DLB). Background: Dementia with Lewy bodies is a progressive disabling neurodegenerative disease with…Comparison of 123I-MIBG myocardial scintigraphy and 123I-FP-CIT SPECT between dementia with Lewy bodies and Parkinson’s disease
Objective: The objective of this study was to compare the nuclear medicine images of dementia with Lewy bodies (DLB) and Parkinson's disease (PD) patients and to extract findings…An Informant-based Simple Questionnaire for Executive Function Assessment in Dementia with Lewy Bodies and Alzheimer’s Disease
Objective: The aim of this study was to investigate and compare executive dysfunction by using a newly designed informant-based simple questionnaire among patients with DLB…Efficacy and safety of zonisamide in patients with dementia with Lewy bodies with parkinsonism: pooled analysis of phase 2 and 3 trials
Objective: To characterize the efficacy and safety of zonisamide (ZNS) in patients with dementia with Lewy bodies (DLB) with parkinsonism, a pooled analysis of two…Anterior EEG slowing in Dementia with Lewy Bodies: a multicenter European cohort study
Objective: to analyse the anterior-posterior scalp distribution of dominant frequencies with an intra-subject evaluation in a dementia with Lewy bodies patient group. Background: EEG slowing…Effects of zonisamide on parkinsonism in patients with dementia with Lewy bodies by severity of cognitive dysfunction and BPSD: subgroup analysis of pooled data from two trials
Objective: To characterize the efficacy and safety of zonisamide (ZNS) in patients with dementia with Lewy bodies (DLB) with parkinsonism, we performed subgroup analysis by…Visual evoked potentials alterations in DLB
Objective: To investigate whether DLB and PD patients show VEP and OCT alterations in comparison with AD patients, and whether this possible alterations are associated…Preclinical profile of dopamine D1PAM: A novel mechanism in clinical development for Lewy Body dementia
Objective: Introduce the mechanism of action for dopamine D1 positive allosteric modulator (D1PAM) as a new target for neuropsychiatric disorders. Describe the preclinical profile of…Brain amyloid contribution to cognitive dysfunction in Lewy bodies disorders: a pilot study
Objective: To investigate regional [18F]florbetapir binding to amyloid-β and its contribution to cognitive dysfunction in Lewy bodies disorders. Background: Lewy bodies disorders like Parkinson’s disease…Functional exam findings in Lewy Body Disease
Objective: Case study to review functional exam findings in an abnormal Dopaminergic transporter scan positive Lewy body dementia patient. Background: Patient presented with known Parkinson’s…
- « Previous Page
- 1
- …
- 12
- 13
- 14
- 15
- 16
- …
- 23
- Next Page »